Jing Fei

Shihezi, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study.

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study.

Journal: Frontiers in oncology

Published: June 02, 2026

Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy.

Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy.

Journal: Journal of translational medicine

Published: December 25, 2025

Breaking the oncogene-immune suppression cycle through dual HER2 silencing and innate immune activation by biomineralized DNA nanocomplexes.

Breaking the oncogene-immune suppression cycle through dual HER2 silencing and innate immune activation by biomineralized DNA nanocomplexes.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: December 23, 2025

Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.

Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.

Journal: Current treatment options in oncology

Published: November 12, 2025

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 18, 2025

Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment.

Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment.

Journal: World journal of gastrointestinal oncology

Published: October 06, 2024

High microvessel and lymphatic vessel density predict poor prognosis in patients with esophageal squamous cell carcinoma.

High microvessel and lymphatic vessel density predict poor prognosis in patients with esophageal squamous cell carcinoma.

Journal: PeerJ

Published: May 03, 2024

Spatial heterogeneity and prognostic significance of TAMs and TILs infiltrates in different staging esophageal squamous carcinoma.

Spatial heterogeneity and prognostic significance of TAMs and TILs infiltrates in different staging esophageal squamous carcinoma.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 18, 2024

M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma.

M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma.

Journal: Journal of translational medicine

Published: August 27, 2022

Inhibition of SNCG suppresses the proliferation of lung cancer cells induced by high glucose.

Inhibition of SNCG suppresses the proliferation of lung cancer cells induced by high glucose.

Journal: Molecular medicine reports

Published: July 19, 2020

Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Journal: Cancer research

Published: December 05, 2013

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.

Journal: Gut

Published: June 15, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026